- ICH GCP
- Rejestr badań klinicznych w USA
- Badanie kliniczne NCT02520791
Przeciwciało monoklonalne anty-ICOS MEDI-570 w leczeniu pacjentów z nawracającym lub opornym na leczenie chłoniakiem z obwodowych komórek T Wariant grudkowy lub chłoniak z angioimmunoblastycznych komórek T
Badanie I fazy MEDI-570 u pacjentów z nawracającym/opornym na leczenie chłoniakiem z obwodowych komórek T (PTCL) w wariancie grudkowym i chłoniakiem angioimmunoblastycznym z komórek T (AITL)
This phase I trial studies the side effects and best dose of anti-inducible T-cell co-stimulator (ICOS) monoclonal antibody MEDI-570 in treating patients with peripheral T-cell lymphoma follicular variant or angioimmunoblastic T-cell lymphoma that has returned after a period of improvement (relapsed) or has not responded to previous treatment (refractory). Immunotherapy with monoclonal antibodies, such as anti-ICOS monoclonal antibody MEDI-570, may induce changes in the body's immune system and may interfere with the ability of tumor cells to grow and spread.
Przegląd badań
Status
Warunki
- Nawracający chłoniak grudkowy 1 stopnia
- Nawracający chłoniak grudkowy stopnia 2
- Zaawansowany pierwotny chłoniak nieziarniczy skóry T-komórkowy
- Nawracający chłoniak grudkowy stopnia 3a
- Nawracający chłoniak nieziarniczy z dojrzałych komórek T i komórek NK
- Nawracające ziarniniaki grzybicze
- Nawracający pierwotny chłoniak nieziarniczy skórny T-komórkowy
- Oporny na leczenie chłoniak grudkowy 1. stopnia
- Oporny na leczenie chłoniak grudkowy 2. stopnia
- Oporny na leczenie chłoniak grudkowy stopnia 3a
- Oporny na leczenie chłoniak nieziarniczy z dojrzałych komórek T i komórek NK
- Stadium IB Ziarniniak grzybiasty AJCC v7
- Ziarniniak grzybiasty stopnia II AJCC v7
- Stopień III skórnego chłoniaka nieziarniczego T-komórkowego
- Stadium III Ziarniniak grzybiasty AJCC v7
- Stopień IV skórny chłoniak nieziarniczy T-komórkowy
- Stopień IV Ziarniniak grzybiasty AJCC v7
- Nawracający chłoniak pęcherzykowy pomocniczy z komórek T typu angioimmunoblastycznego
- Oporny chłoniak pęcherzykowy pomocniczy z komórek T typu angioimmunoblastycznego
Szczegółowy opis
PRIMARY OBJECTIVE:
I. To determine the safety, maximum tolerated dose and recommended phase II dose (RP2D) of anti-ICOS monoclonal antibody MEDI-570 (MEDI-570) in patients with refractory/relapsed peripheral T-cell lymphoma-not otherwise specified (PTCL-NOS), angioimmunoblastic T-cell lymphoma (AITL), follicular lymphoma, mycosis fungoides (MF) and cutaneous T-cell lymphomas (CTCL).
SECONDARY OBJECTIVES:
I. To evaluate the pharmacokinetic profile of MEDI-570. II. To evaluate the overall response rate (ORR) and progression free survival (PFS) of MEDI-570 at all dose levels and in a 10-patient expansion cohort at the maximum tolerated dose (MTD).
III. To determine short and long term effects of MEDI-570 at all dose levels on the immune system and on T-cell lymphocyte subsets.
IV. To determine the relationship between ICOS expression on tumor cells and response to MEDI-570.
EXPLORATORY OBJECTIVE:
I. To evaluate biomarkers of response and resistance to MEDI-570 in the study population.
OUTLINE: This is a dose-escalation study.
Patients receive anti-ICOS monoclonal antibody MEDI-570 intravenously (IV) over 1-4 hours on day 1. Treatment repeats every 21 days for up to 8 cycles in the absence of disease progression or unacceptable toxicity.
After completion of study treatment, patients are followed up at 30 days and then every 6 weeks for 12 weeks.
Typ studiów
Zapisy (Rzeczywisty)
Faza
- Faza 1
Kontakty i lokalizacje
Lokalizacje studiów
-
-
British Columbia
-
Vancouver, British Columbia, Kanada, V5Z 4E6
- BCCA-Vancouver Cancer Centre
-
-
Ontario
-
Toronto, Ontario, Kanada, M5G 2M9
- University Health Network-Princess Margaret Hospital
-
-
-
-
California
-
Duarte, California, Stany Zjednoczone, 91010
- City of Hope Comprehensive Cancer Center
-
Sacramento, California, Stany Zjednoczone, 95817
- University of California Davis Comprehensive Cancer Center
-
-
Connecticut
-
New Haven, Connecticut, Stany Zjednoczone, 06520
- Yale University
-
New Haven, Connecticut, Stany Zjednoczone, 06510
- Smilow Cancer Center/Yale-New Haven Hospital
-
-
Florida
-
Tampa, Florida, Stany Zjednoczone, 33612
- Moffitt Cancer Center
-
-
Illinois
-
Chicago, Illinois, Stany Zjednoczone, 60637
- University of Chicago Comprehensive Cancer Center
-
-
Kansas
-
Fairway, Kansas, Stany Zjednoczone, 66205
- University of Kansas Clinical Research Center
-
-
Kentucky
-
Lexington, Kentucky, Stany Zjednoczone, 40536
- University of Kentucky/Markey Cancer Center
-
-
Missouri
-
Creve Coeur, Missouri, Stany Zjednoczone, 63141
- Siteman Cancer Center at West County Hospital
-
St Louis, Missouri, Stany Zjednoczone, 63110
- Washington University School of Medicine
-
St Louis, Missouri, Stany Zjednoczone, 63129
- Siteman Cancer Center-South County
-
-
Nebraska
-
Omaha, Nebraska, Stany Zjednoczone, 68198
- University of Nebraska Medical Center
-
-
New York
-
Buffalo, New York, Stany Zjednoczone, 14263
- Roswell Park Cancer Institute
-
The Bronx, New York, Stany Zjednoczone, 10461
- Montefiore Medical Center-Einstein Campus
-
The Bronx, New York, Stany Zjednoczone, 10467
- Montefiore Medical Center - Moses Campus
-
The Bronx, New York, Stany Zjednoczone, 10461
- Montefiore Medical Center-Weiler Hospital
-
-
North Carolina
-
Durham, North Carolina, Stany Zjednoczone, 27710
- Duke University Medical Center
-
-
Ohio
-
Columbus, Ohio, Stany Zjednoczone, 43210
- Ohio State University Comprehensive Cancer Center
-
-
Texas
-
Dallas, Texas, Stany Zjednoczone, 75390
- UT Southwestern/Simmons Cancer Center-Dallas
-
Houston, Texas, Stany Zjednoczone, 77030
- Baylor College of Medicine/Dan L Duncan Comprehensive Cancer Center
-
-
Utah
-
Salt Lake City, Utah, Stany Zjednoczone, 84112
- Huntsman Cancer Institute/University of Utah
-
-
Kryteria uczestnictwa
Kryteria kwalifikacji
Wiek uprawniający do nauki
Akceptuje zdrowych ochotników
Płeć kwalifikująca się do nauki
Opis
Inclusion Criteria:
-
Pathologic diagnosis of one of the following:
-
For dose escalation:
-
Confirmed diagnosis of peripheral T-cell lymphoma (PTCL) or angioimmunoblastic T-cell lymphoma (AITL) that is refractory to at least one line of therapy; anaplastic large cell lymphoma (ALCL) and natural killer T-cell lymphoma nasal type (NKTCL) are excluded
-
Advanced stage cutaneous T-cell lymphoma (CTCL), specifically CTCL NOS, small/medium T-cell lymphoma (SMTCL) and mycosis fungoides (MF) stage IB, IIA, IIB, III and IV that have relapsed after at least one specific prior therapy (e.g. interferon, photopheresis, denileukin difitox, bexarotene, etc); anaplastic cutaneous large cell lymphoma (ACLCL) and lymphomatoid papulopsis are excluded
-
Follicular lymphoma grade 1, 2 or 3A that meets the following criteria:
- Relapsed or refractory to at least 2 lines of therapy AND
- Relapsed or refractory post autologous cell transplantation (HCT)
-
-
For dose expansion/dose confirmation phase:
- Patients with confirmed diagnosis of peripheral T-cell lymphoma (PTCL) follicular type or angioimmunoblastic T-cell lymphoma (AITL) that is refractory to at least one line of therapy
-
-
At least 14 days from the last therapy dose or 5 half-lives (whichever is shorter), and resolution of toxicity related to the last therapy, excluding grade 2 or less peripheral neuropathy and alopecia; for radiation therapy, a minimum of 2 weeks and resolution of all acute toxicity will be required
-
Patients must have at least one measurable lesion that can be accurately measured with spiral computed tomography (CT) scan, magnetic resonance imaging (MRI) scan, or physical exam (by calipers only); (PTCL, AITL and follicular lymphoma patients will be assessed on this study using the Lugano criteria for the evaluation of lymphomas; CTCL and MF patients will be assessed using International Society for Cutaneous Lymphomas [ISCL] and European Organization for Research and Treatment of Cancer [EORTC] criteria)
-
Eastern Cooperative Oncology Group (ECOG) performance status =< 2 (Karnofsky >= 60%)
-
Life expectancy of greater than 6 months
-
Leukocytes >= 3,000/mcL
-
Hemoglobin >= 80 d/L (or >= 8 g/dL)
- Patients must not have received a transfusion, with packed red blood cells, within 2 weeks prior to sample being collected
-
Absolute neutrophil count (ANC) >= 1,500/mcL
-
Platelets (PLT) >= 50,000/mcL
-
Absolute CD4 count > 100 cells/uL
-
Total bilirubin < 1.5 upper limit of normal (ULN)
-
Aspartate aminotransferase (AST) (serum glutamic oxaloacetic transaminase [SGOT])/alanine aminotransferase (ALT) (serum glutamic pyruvic transaminase [SGPT]) =< 2.5 x institutional upper limit of normal
-
Creatinine < 1.5 mg/dl (= 132 umol/L) or
-
Creatinine clearance >= 50 mL/min/1.73 m^2 for patients with creatinine levels above institutional normal
-
In patients with bone marrow involvement the minimum requirement is as follows:
- Leukocytes >= 2000/mcL
- ANC >= 1000/mcL
- PLT >= 50 000/mcL
-
Availability of tissue for correlative studies; patients must have at least 6-8 unstained slides of archived formalin-fixed, paraffin-embedded tumor tissue available; if not enough archived tissue is available, a fresh tumor biopsy prior to study initiation is mandatory; for patients who have undergone a fresh baseline biopsy at baseline, the archived tissue is not mandatory
-
The effects of MEDI-570 on the developing human fetus are unknown; for this reason, women of child-bearing potential and men must agree to use adequate contraception (hormonal or barrier method of birth control; abstinence) prior to study entry, during the study participation, and for 3 months after the last dose of the drug; should a woman become pregnant or suspect she is pregnant while she or her partner is participating in this study, she should inform her treating physician immediately; men treated or enrolled on this protocol must have either had a prior vasectomy or agree to use effective contraception prior to the study, during the study, and for 3 months after the last dose of the drug; males should avoid fathering children during and for at least three months after therapy is completed
-
Ability to understand and the willingness to sign a written informed consent document
Exclusion Criteria:
-
Patients who are receiving any other investigational agents
-
Patients with known brain metastases should be excluded from this clinical trial because of their poor prognosis and because they often develop progressive neurologic dysfunction that would confound the evaluation of neurologic and other adverse events
-
History of allergic reactions attributed to compounds of similar chemical or biologic composition to MEDI-570 or history of anaphylaxis to any biological component
-
Any history or evidence of opportunistic infection within 6 months of screening including tuberculosis, severe cytomegalovirus (CMV) or herpetic infections (such as disseminated herpes, herpes encephalitis, ophthalmic herpes)
-
Evidence of active infection by hepatitis B and/or C; active viral infection by hepatitis B and hepatitis C could be associated with cytopenias (due to hypersplenism or due to the active virus itself), which could add further risk when a potential immunosuppressive medication is used; for patients with hepatitis B treated with anti-virals to undetectable viral load, and for patients with hepatitis C with undetectable ribonucleic acid (RNA) levels and no evidence of liver damage, enrollment may be considered and should discuss first with study's principal investigator
-
History of human immunodeficiency virus (HIV) infection; the human immunodeficiency virus (HIV) depletes CD4 T-cells and could also have a role in T-cell anergy; since MEDI-570 preferentially affects CD4 T-cell numbers and function, and the resultant immunosuppression by this agent can be prolonged, exposing HIV patients to MEDI-570 will place them in an unnecessary risk of developing infections due to an underlying acquired cellular immunity defect
-
History of primary immunodeficiency
-
Receipt of live or live attenuated vaccine within 12 weeks prior to enrollment
-
All potential patients must undergo a tuberculosis (TB) test prior to study entry to rule out active or latent tuberculosis (either purified protein derivative [PPD] or QuantiFERON-TB Gold, whichever is preferred and available at the institution); patients with a history of TB (even if treated), or evidence of active or latent TB, are excluded; the diagnosis of active TB is defined per current guidelines; patients with a positive TB test (e.g. PPD or QuantiFERON-TB Gold) will be excluded; patients with history of Bacille-Calmette-Guerin (BCG) vaccination will be tested with QuantiFERON-TB Gold test in order to rule out exposure to TB
-
Patients who have undergone allogeneic stem cell transplantation
-
Patients who have undergone autologous stem cell transplantation within 3 months from study entry
-
Major surgery within 30 days prior or during the study period
-
Uncontrolled intercurrent illness including, but not limited to, ongoing or active infection, symptomatic congestive heart failure, unstable angina pectoris, cardiac arrhythmia, or psychiatric illness/social situations that would limit compliance with study requirements
-
Pregnant women are excluded from this study due to the potential toxicity in pre-clinical reproductive studies; in addition, there is an unknown but potential risk for adverse events in nursing infants secondary to treatment of the mother with MEDI-570; breastfeeding should be discontinued if the mother is treated with MEDI-570
-
Patients with active, known, or suspected autoimmune disease, except in these conditions:
-
Participants with well-controlled asthma and/or mild allergic rhinitis (seasonal allergies) are eligible
-
Participants with the following disease conditions are also eligible:
- Vitiligo,
- Type 1 diabetes mellitus
- Residual hypothyroidism due to autoimmune condition only requiring hormone replacement
- Euthyroid participants with a history of Grave's disease (participants suspected autoimmune thyroid disorders must be negative for thyroglobulin and thyroid peroxidase antibodies and thyroid stimulating immunoglobulin prior to first dose of study drug)
- For patients with ITP (idiopathic thrombocytopenic purpura) or AIHA (autoimmune hemolytic anemia), a case by case discussion with study principal investigator (PI) may be considered
- Patients not receiving systemic therapy (i.e., systemic steroids or biologic therapy with disease modifying anti-rheumatic drugs [DMARDs]) within 2 years can be also eligible
-
-
Patients with a weight of < 39 kg
Plan studiów
Jak projektuje się badanie?
Szczegóły projektu
- Główny cel: Leczenie
- Przydział: Nie dotyczy
- Model interwencyjny: Zadanie dla jednej grupy
- Maskowanie: Brak (otwarta etykieta)
Broń i interwencje
Grupa uczestników / Arm |
Interwencja / Leczenie |
|---|---|
|
Eksperymentalny: Treatment (MEDI-570)
Patients receive anti-ICOS monoclonal antibody MEDI-570 IV over 1-4 hours on day 1. Treatment repeats every 21 days for up to 8 cycles in the absence of disease progression or unacceptable toxicity. |
Correlative studies Correlative studies Given IV
Inne nazwy:
|
Co mierzy badanie?
Podstawowe miary wyniku
Miara wyniku |
Opis środka |
Ramy czasowe |
|---|---|---|
|
Incidence of toxicity and safety of anti-inducible T-cell co-stimulator (ICOS) monoclonal antibody MEDI-570
Ramy czasowe: Up to 12 weeks after completion of study treatment
|
Graded according to the National Cancer Institute (NCI) Common Terminology Criteria for Adverse Events (CTCAE) version 5.0. Frequency and severity of adverse events will be tabulated using counts and proportions detailing frequently occurring, serious and severe events of interest. Adverse events will be summarized using all adverse events experienced, although a sub-analysis may be conducted including only those adverse events in which the treating physician deems possibly, probably or definitely attributable to one or both study treatments. |
Up to 12 weeks after completion of study treatment
|
|
Maximum tolerated dose (MTD) of anti-inducible T-cell co-stimulator (ICOS) monoclonal antibody MEDI-570
Ramy czasowe: Up to 21 days
|
Toxicity will be assessed using the NCI CTCAE, version 5.0. |
Up to 21 days
|
|
Recommended phase 2 dose of anti-inducible T-cell co-stimulator (ICOS) monoclonal antibody MEDI-570
Ramy czasowe: Up to 21 days
|
Toxicity will be assessed using the NCI CTCAE, version 5.0. |
Up to 21 days
|
Miary wyników drugorzędnych
Miara wyniku |
Opis środka |
Ramy czasowe |
|---|---|---|
|
Pharmacokinetics (PK), such as plasma concentration and PK parameters, of monoclonal antibody therapy
Ramy czasowe: Prior to dose on day 1, immediately after dose, and at 6 minutes, 24, 48 and 72 hours post dose of cycle 1 and cycle 2, and then on day 1 pre-dose of every subsequent cycle
|
Attempts to model associations between pharmacokinetic data with toxicity profiles will be performed primarily using descriptive statistics; however, logistic regression may be used if warranted. |
Prior to dose on day 1, immediately after dose, and at 6 minutes, 24, 48 and 72 hours post dose of cycle 1 and cycle 2, and then on day 1 pre-dose of every subsequent cycle
|
|
Overall response rate
Ramy czasowe: Up to 36 weeks
|
Assessed per the Revised Response Criteria for Malignant Lymphoma of the Lugano Classification. Summary statistics, such as the mean, median, counts and proportion, will be used to describe patients' clinical characteristics. For all statistical tests, two-sided tests will be performed and no p-value adjustment performed due to the exploratory nature of these tests. A p-value of 0.05 or less will be considered statistically significant. |
Up to 36 weeks
|
|
Progression-free survival
Ramy czasowe: Up to 12 weeks after completion of study treatment
|
Summary statistics, such as the mean, median, counts and proportion, will be used to describe patients' clinical characteristics. For all statistical tests, two-sided tests will be performed and no p-value adjustment performed due to the exploratory nature of these tests. A p-value of 0.05 or less will be considered statistically significant. |
Up to 12 weeks after completion of study treatment
|
|
Immunogenicity
Ramy czasowe: Up to 36 weeks
|
Summary statistics, such as the mean, median, counts and proportion, will be used to describe patients' clinical characteristics. For all statistical tests, two-sided tests will be performed and no p-value adjustment performed due to the exploratory nature of these tests. A p-value of 0.05 or less will be considered statistically significant. |
Up to 36 weeks
|
|
Overall survival (OS)
Ramy czasowe: Up to 12 weeks after completion of study treatment
|
Summary statistics, such as the mean, median, counts and proportion, will be used to describe patients' clinical characteristics. For all statistical tests, two-sided tests will be performed and no p-value adjustment performed due to the exploratory nature of these tests. A p-value of 0.05 or less will be considered statistically significant. |
Up to 12 weeks after completion of study treatment
|
Inne miary wyników
Miara wyniku |
Opis środka |
Ramy czasowe |
|---|---|---|
|
Biomarkers of response and resistance to anti-inducible T-cell co-stimulator (ICOS) monoclonal antibody MEDI-570
Ramy czasowe: Up to 36 weeks
|
Predictors of clinical outcomes will be investigated using logistic regression, Cox proportional hazards regression and/or generalized estimating equations as appropriate. Potential predictors include clinical predictors and molecular correlates. Descriptive statistics and plotting of data will also be used to better understand potential relationships. |
Up to 36 weeks
|
Współpracownicy i badacze
Sponsor
Śledczy
- Główny śledczy: Julio C Chavez, University Health Network Princess Margaret Cancer Center LAO
Publikacje i pomocne linki
Daty zapisu na studia
Główne daty studiów
Rozpoczęcie studiów (Rzeczywisty)
Zakończenie podstawowe (Rzeczywisty)
Ukończenie studiów (Szacowany)
Daty rejestracji na studia
Pierwszy przesłany
Pierwszy przesłany, który spełnia kryteria kontroli jakości
Pierwszy wysłany (Szacowany)
Aktualizacje rekordów badań
Ostatnia wysłana aktualizacja (Rzeczywisty)
Ostatnia przesłana aktualizacja, która spełniała kryteria kontroli jakości
Ostatnia weryfikacja
Więcej informacji
Terminy związane z tym badaniem
Dodatkowe istotne warunki MeSH
- Nowotwory
- Choroby układu odpornościowego
- Nowotwory według typu histologicznego
- Choroby limfatyczne
- Zaburzenia limfoproliferacyjne
- Zaburzenia immunoproliferacyjne
- Chłoniak nieziarniczy
- Chłoniak
- Choroby hemowe i limfatyczne
- Chłoniak, Pęcherzykowy
- Chłoniak, T-komórkowy
- Chłoniak T-komórkowy, skórny
- Ziarniniak grzybiasty
- MEDI-570
Inne numery identyfikacyjne badania
- NCI-2015-01271
- UM1CA186644 (Grant/umowa NIH USA)
- NCI-2015-01271 (Identyfikator rejestru: CTRP (Clinical Trial Reporting Program))
- PJC-021
- 9930 (Inny identyfikator: CTEP)
- 9930 (Inny identyfikator: University Health Network Princess Margaret Cancer Center LAO)
Te informacje zostały pobrane bezpośrednio ze strony internetowej clinicaltrials.gov bez żadnych zmian. Jeśli chcesz zmienić, usunąć lub zaktualizować dane swojego badania, skontaktuj się z register@clinicaltrials.gov. Gdy tylko zmiana zostanie wprowadzona na stronie clinicaltrials.gov, zostanie ona automatycznie zaktualizowana również na naszej stronie internetowej .